GLP-1 Constipation: What Labels Report

Semaglutide: two injection evidence sets

Ozempic section 6.1 reports constipation in 5.0% at 0.5 mg and 3.1% at 1 mg, compared with 1.5% on placebo. Those data come from the pooled adult type 2 diabetes monotherapy and basal-insulin studies. Wegovy Table 3 describes a different pool: adult weight-management Studies 2, 3, and 4 using 2.4 mg weekly, with constipation reported in 24% versus 11% on placebo. Ozempic label Wegovy label

Both use the active ingredient semaglutide, but that does not make the study populations or doses interchangeable. The labels explicitly caution against direct comparisons of adverse-reaction rates across differently conducted studies. The numbers can be displayed together to identify their provenance, but they cannot establish that one product will produce more or less constipation for an individual reader. Ozempic label Wegovy label

Tirzepatide: retain the brand and study pool

Zepbound pooled Study 1 and Study 2 reported constipation in 17%, 14%, and 11% at 5, 10, and 15 mg, compared with 5% on placebo. The footnote includes hard stools in the category. Mounjaro pooled SURPASS-1 and SURPASS-5 adult diabetes data reported 6%, 6%, and 7% at the same assigned strengths, compared with 1% on placebo. Zepbound label Mounjaro label

These rows represent different evidence sets. The Zepbound percentages decrease across the assigned-dose columns, while the Mounjaro values do not follow the same pattern. Neither pattern supplies a personal dose-adjustment rule. It is more accurate to retain the published group descriptions than to turn a table shape into a prediction about what happens after a medication change. Zepbound label Mounjaro label

Constipation reports: label-defined study pools, not a head-to-head comparison Ozempic label Wegovy label Zepbound label Mounjaro label
Product / study pool	Dose group	Reported / placebo
Ozempic monotherapy + basal insulin	0.5 / 1 mg	5.0% / 3.1%; placebo 1.5%
Wegovy Studies 2–4	2.4 mg	24%; placebo 11%
Zepbound Studies 1–2	5 / 10 / 15 mg	17% / 14% / 11%; placebo 5%
Mounjaro SURPASS-1 and SURPASS-5	5 / 10 / 15 mg	6% / 6% / 7%; placebo 1%

Frequency does not supply a personal explanation

The label percentages describe reported events during studies. They do not establish how many days a particular episode lasted or why a particular person experienced it. Postmarketing reports are another evidence category, with uncertain population size and limits on estimating frequency or causation. A study table and a voluntary-report list should not be presented as the same kind of measurement. Ozempic label Wegovy label Zepbound label Mounjaro label

This page does not infer an individual mechanism, suggest a remedy, or use the presence of constipation as a reason to choose a different amount of medication. Its scope is the label evidence: which population was observed, which amount was assigned, what category was reported, and what the source says about interpretation. Those boundaries keep a factual reference from becoming an unsupported treatment plan.

Keep observations attached to dates

PinPoint supports daily notes and side-effect severity ratings, as well as injection logs with compound, dose, site, and pain level. Backfilling earlier doses can preserve context around a dated observation. These features make a history available for review without claiming that the app can determine the cause of a symptom or diagnose a gastrointestinal condition. App features

The app also supports PDF, CSV, and JSON export. A record can retain the observation as written, the date logged, and the surrounding prescribed phase. The modeled-level graph remains a mathematical reference based on population averages rather than a clinical test. Talk to the prescriber about new, persistent, or concerning constipation. App features

Useful distinctions

Questions

Is constipation listed for both semaglutide and tirzepatide?

Yes. The cited Ozempic, Wegovy, Mounjaro, and Zepbound adverse-reaction sections all report constipation, with different study populations and dose-specific percentages. Ozempic label Wegovy label Mounjaro label Zepbound label

Do the tables tell me which product will cause fewer symptoms?

No. The labels caution against direct comparisons across differently conducted studies. The percentages provide source-specific context rather than a personalized ranking. Ozempic label Wegovy label Mounjaro label Zepbound label

Your record, together

Keep the details attached to the date.

Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.

Get PinPoint on the App Store

Sources & scope

Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.

PinPoint feature description
Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.
How to read this reference
Editorial organization, explicit scope limits, and interpretation of the cited label or app evidence. No additional medical facts.
Mounjaro prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
Ozempic prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: adec4fd2-6858-4c99-91d4-531f5f2a2d79.
Wegovy prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: ee06186f-2aa3-4990-a760-757579d8f77b.
Zepbound prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: 487cd7e7-434c-4925-99fa-aa80b1cc776b.